See more : Ashiana Ispat Limited (ASHIS.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Innate Pharma S.A. (IPHA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Innate Pharma S.A., a leading company in the Biotechnology industry within the Healthcare sector.
- Meiloon Industrial Co., Ltd. (2477.TW) Income Statement Analysis – Financial Results
- Media Sentiment, Inc. (MSEZ) Income Statement Analysis – Financial Results
- Dialogue Health Technologies Inc. (CARE.TO) Income Statement Analysis – Financial Results
- CNB Financial Corporation (CCNE) Income Statement Analysis – Financial Results
- Glacier Lake Resources Inc. (GLI.V) Income Statement Analysis – Financial Results
Innate Pharma S.A. (IPHA)
About Innate Pharma S.A.
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51.90M | 49.64M | 12.11M | 56.83M | 68.97M | 79.89M | 32.63M | 56.16M | 17.91M | 907.00K | 12.47M | 10.38M | 11.74M | 4.32M | 7.72M | 12.92M | 14.29M | 6.20M | 1.30M |
| Cost of Revenue | 56.02M | 51.66M | 47.00M | 3.04M | 45.16M | 69.56M | 67.00M | 48.63M | 29.91M | 12.09M | 7.58M | 6.86M | 1.64M | 3.43M | 3.35M | 2.56M | 2.77M | 2.20M | 944.00K |
| Gross Profit | -4.12M | -2.02M | -34.89M | 53.79M | 23.82M | 10.34M | -34.37M | 7.53M | -12.00M | -11.18M | 4.89M | 3.51M | 10.10M | 893.00K | 4.37M | 10.37M | 11.52M | 3.99M | 356.00K |
| Gross Profit Ratio | -7.94% | -4.08% | -288.08% | 94.65% | 34.53% | 12.94% | -105.33% | 13.41% | -67.02% | -1,232.64% | 39.22% | 33.86% | 86.05% | 20.67% | 56.62% | 80.21% | 80.64% | 64.47% | 27.38% |
| Research & Development | 56.02M | 51.66M | 47.00M | 58.61M | 1.60M | 69.56M | 67.00M | 48.63M | 29.91M | 22.67M | 15.13M | 13.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 11.75M | 14.47M | 15.99M | 31.25M | 40.73M | 18.14M | 15.66M | 8.88M | 5.59M | 12.50M | 10.38M | 9.33M | 0.00 | 6.27M | 8.52M | 0.00 | 0.00 | 1.64M | 938.00K |
| Selling & Marketing | 0.00 | 7.96M | 9.53M | -861.00K | 8.85M | 1.11M | 527.00K | 450.00K | 288.00K | 314.00K | 283.00K | 406.00K | 9.79M | 7.06M | 10.06M | 0.00 | 0.00 | 207.00K | 139.00K |
| SG&A | 11.75M | 22.44M | 25.52M | 30.39M | 49.58M | 19.25M | 16.18M | 9.33M | 5.88M | 12.82M | 10.67M | 9.73M | 9.79M | 7.06M | 10.06M | 0.00 | 0.00 | 1.84M | 1.08M |
| Other Expenses | -3.20M | -8.04M | -12.59M | -13.62M | -309.00K | -14.06M | -10.57M | -9.37M | -7.11M | -19.00K | 179.00K | 2.00K | 7.88M | 32.00K | 909.00K | 21.37M | 20.62M | 9.34M | 5.69M |
| Operating Expenses | 64.57M | 66.06M | 59.94M | 75.38M | 50.87M | 74.75M | 72.61M | 48.59M | 28.68M | 8.76M | 7.66M | 6.88M | 17.67M | 14.58M | 19.90M | 21.37M | 20.62M | 11.18M | 6.77M |
| Cost & Expenses | 64.57M | 66.06M | 59.94M | 75.38M | 96.03M | 74.75M | 72.61M | 48.59M | 28.68M | 20.85M | 15.24M | 13.75M | 19.31M | 18.01M | 23.25M | 23.93M | 23.38M | 13.38M | 7.72M |
| Interest Income | 3.18M | 4.78M | 6.34M | 4.86M | 1.62M | 1.58M | 1.25M | 0.00 | 27.00K | 445.00K | 244.00K | 34.00K | 945.00K | 541.00K | 0.00 | 1.19M | 212.00K | 1.20M | 280.00K |
| Interest Expense | 640.00K | 5.32M | 4.00M | 6.76M | 204.00K | 102.00K | 113.00K | 124.00K | 139.00K | 0.00 | 0.00 | 225.00K | 520.00K | 509.00K | 0.00 | 36.00K | 39.00K | 2.00K | 0.00 |
| Depreciation & Amortization | 5.09M | 4.42M | 4.57M | 9.39M | 16.53M | 7.40M | 4.40M | 3.26M | 2.66M | 2.34M | 880.00K | 839.00K | 901.00K | 1.10M | 1.02M | 539.00K | 536.00K | 298.00K | 301.00K |
| EBITDA | -1.84M | -61.30M | -43.23M | 43.11M | -20.86M | -3.30M | -35.65M | 10.83M | -8.09M | -17.14M | -1.91M | -1.76M | -5.80M | -12.32M | -14.47M | -12.48M | -8.50M | -6.94M | -6.11M |
| EBITDA Ratio | -3.54% | 68.00% | -304.53% | 75.85% | -12.88% | 15.48% | -109.25% | 20.73% | -45.18% | -1,967.81% | -17.70% | -27.62% | -47.19% | -291.44% | -187.48% | -80.99% | -59.51% | -91.90% | -448.31% |
| Operating Income | -12.67M | -11.65M | -47.83M | -13.69M | -27.05M | 5.15M | -39.98M | 7.57M | -10.77M | -19.97M | -2.79M | -3.39M | -7.57M | -13.69M | -15.54M | -11.01M | -9.09M | -7.24M | -6.42M |
| Operating Income Ratio | -24.41% | -23.47% | -394.86% | -24.09% | -39.22% | 6.44% | -122.53% | 13.48% | -60.16% | -2,201.32% | -22.40% | -32.63% | -64.48% | -316.90% | -201.33% | -85.16% | -63.62% | -116.85% | -493.46% |
| Total Other Income/Expenses | 5.10M | -547.00K | 2.35M | -15.53M | 6.29M | -2.43M | -8.03M | 5.37M | 4.07M | 319.00K | -99.00K | 183.00K | 590.00K | 32.00K | 909.00K | 1.15M | 173.00K | 1.20M | 286.00K |
| Income Before Tax | -7.57M | -57.97M | -45.48M | -63.98M | -20.76M | 2.72M | -48.02M | 12.94M | -6.71M | -19.65M | -2.89M | -3.20M | -6.98M | -13.66M | -14.63M | -9.85M | -8.92M | -6.04M | -6.13M |
| Income Before Tax Ratio | -14.59% | -116.79% | -375.48% | -112.58% | -30.10% | 3.40% | -147.15% | 23.04% | -37.45% | -2,166.15% | -23.19% | -30.83% | -59.45% | -316.16% | -189.55% | -76.23% | -62.41% | -97.53% | -471.46% |
| Income Tax Expense | 0.00 | 41.13M | 13.66M | 6.76M | 206.00K | -333.00K | 368.00K | 301.00K | 139.00K | -24.00K | -51.00K | -146.00K | 1.13M | 0.00 | 46.00K | 0.00 | 51.00K | 1.20M | 286.00K |
| Net Income | -7.57M | -99.10M | -59.14M | -70.75M | -20.97M | 3.05M | -48.39M | 12.64M | -6.71M | -19.65M | -2.89M | -3.20M | -6.98M | -13.66M | -14.63M | -9.85M | -8.92M | -6.04M | -6.13M |
| Net Income Ratio | -14.59% | -199.65% | -488.24% | -124.48% | -30.40% | 3.82% | -148.28% | 22.51% | -37.45% | -2,166.15% | -23.19% | -30.83% | -59.45% | -316.16% | -189.55% | -76.23% | -62.41% | -97.53% | -471.46% |
| EPS | -0.09 | -1.24 | -0.74 | -0.90 | -0.31 | 0.05 | -0.89 | 0.23 | -0.13 | -0.39 | -0.07 | -0.08 | -0.19 | -0.36 | -0.56 | -0.38 | -0.36 | -0.34 | -0.41 |
| EPS Diluted | -0.09 | -1.24 | -0.74 | -0.90 | -0.31 | 0.05 | -0.89 | 0.23 | -0.13 | -0.39 | -0.07 | -0.08 | -0.19 | -0.36 | -0.56 | -0.38 | -0.36 | -0.34 | -0.41 |
| Weighted Avg Shares Out | 80.45M | 79.64M | 79.54M | 78.93M | 66.91M | 58.78M | 54.35M | 53.87M | 51.58M | 50.15M | 38.70M | 37.80M | 37.69M | 37.44M | 26.30M | 25.67M | 25.08M | 17.77M | 14.90M |
| Weighted Avg Shares Out (Dil) | 80.45M | 79.64M | 79.54M | 78.93M | 66.91M | 58.78M | 54.35M | 53.87M | 53.40M | 50.15M | 38.70M | 37.80M | 37.69M | 37.44M | 26.30M | 25.67M | 25.08M | 17.77M | 14.90M |
Innate Pharma Announces Its Participation to Upcoming Investor Conference
Innate Pharma: Worth A Deeper Look
Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study
Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
Innate Pharma Announces Leadership Change
Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023
Innate Pharma to Host Virtual KOL Event on Lacutamab
Source: https://incomestatements.info
Category: Stock Reports